ALK and neuroblastoma: However, in vivo treatment with single-agent binimetinib in various neuroblastoma cell line-derived xenograft models demonstrated inhibition of tumor growth and extended survival in NRAS or NF1 mutated xenografts while ALK mutated tumors did not respond, likely due to persistent or alternative tyrosine kinase pathway activation [8,93].